Interview: Marc de Garidel – Chairman & CEO, Ipsen, France

faceMarc de Garidel reveals how 2015 has been Ipsen's best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake France to become their number one affiliate. Mr de Garidel also explains Ipsen’s key growth drivers for the next five years: Somatuline, Dysport, and Cabozantinib. 2015 was an important year for Ipsen, why?
"It has been Ipsen´s best year of sales growth since we first became a publicly traded company 10 years ago."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report